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World AIDS Day — December 1, 2013
World AIDS Day draws attention to the current status 
of the human immunodeficiency virus/acquired immuno-
deficiency syndrome (HIV/AIDS) epidemic worldwide. 
The theme for this year’s December 1 observance is 
“Shared Responsibility: Strengthening Results for an 
AIDS-Free Generation.”
The first cases of AIDS were reported more than 32 years 
ago in the June 5, 1981, issue of MMWR. Since then, an 
estimated 36 million persons worldwide have died from 
HIV/AIDS; an estimated 35.3 million persons continue 
to live with HIV infection (1). 
In the United States, approximately 636,000 persons 
with AIDS diagnoses have died since the first cases were 
reported (2); an estimated 1.1 million persons continue 
to live with HIV infection (3).
Global efforts, including the U.S. President’s Emergency 
Plan for AIDS Relief (for which CDC is an implementing 
partner), provided antiretroviral therapy to approximately 
9.7 million persons in low-income and middle-income 
countries in 2012, an increase of 1.6 million persons 
from 2011 (4). 
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Differences Between HIV-Infected 
Men and Women in Antiretroviral 
Therapy Outcomes — Six African 
Countries, 2004–2012
Evaluation of differences between human immunodeficiency 
virus (HIV)-infected men and women in antiretroviral therapy 
(ART) enrollment characteristics and outcomes might identify 
opportunities to improve ART program patient outcomes and 
prevention impact. During September 2008–February 2012, 
retrospective cohort studies to estimate attrition of enrollees 
(i.e., from death, stopping ART, or loss to follow-up) at 
6-month intervals after ART initiation were completed among 
samples of adult men and women (defined as aged ≥15 years or 
aged ≥18 years) who initiated ART during 2004–2010 in six 
African countries: Côte d’Ivoire in western Africa; Swaziland, 
Mozambique, and Zambia in southern Africa; and Uganda 
and Tanzania in eastern Africa. Records for 13,175 ART 
enrollees were analyzed; sample sizes among the six coun-
tries ranged from 1,457 to 3,682. In each country, women 
comprised 61%–67% of ART enrollees. Median CD4 count 
range was 119–141 cells/µL for men and 137–161 cells/µL for 
women. Compared with women, a greater percentage of men 
initiated ART who had World Health Organization (WHO) 
HIV stage IV disease. In cohorts from western Africa and 
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southern Africa, the risk for attrition was 15%–26% lower 
among women compared with men in multivariable analysis. 
However, in eastern Africa, differences between men and 
women in risk for attrition were not statistically significant. 
Research to identify country-specific causes for increased attri-
tion and delayed initiation of care among men could identify 
strategies to improve ART program outcomes among men, 
which might contribute to prevention of new HIV infections 
in female partners.
In each of the six countries, a representative sample of ART 
facilities was selected. To keep the studies feasible, small facili-
ties were excluded from the sample frames of countries with 
>100 ART facilities at the time of sampling. Therefore, in 
Côte d’Ivoire and Mozambique, facilities that had enrolled <50 
adults on ART were excluded, whereas in Zambia, Uganda, 
and Tanzania, facilities that had enrolled <300 adults on ART 
were excluded (Table 1).
From the eligible number of facilities in Côte d’Ivoire (78), 
Swaziland (31), and Mozambique (94), totals of 34, 16, and 
30 study facilities, respectively, were randomly selected using 
probability-proportional-to-size sampling (Table 1). From 
the eligible number of facilities in Zambia (129), Uganda 
(114), and Tanzania (85), six study facilities were purposefully 
(nonrandomly) selected in each country to represent different 
types of ART facilities.
At each selected facility, a sample frame of study-eligible 
ART patients was created, and simple random sampling used 
to select the desired sample size of patient medical records. 
Eligibility criteria included having started ART during 
2004–2010 and ≥6 months before data abstraction. Data 
were abstracted by trained study personnel from ART medical 
records onto standardized abstraction forms. 
Attrition was the primary outcome of interest. A patient 
was considered lost to attrition if the record showed 1) the 
patient had died, 2) the patient had stopped ART because 
of a personal or clinician decision, or 3) the patient had not 
attended the facility in the 90 days preceding data abstraction 
for either medication refill or a clinician visit, in which case 
the patient was considered lost to follow-up. 
Variables routinely collected on Ministry of Health medi-
cal records at ART initiation including sex, age, CD4 count, 
WHO HIV disease stage, and ART regimen, were entered 
into standardized abstraction forms. Data were analyzed using 
statistical software, and study design was controlled for during 
analysis. Data for Côte d’Ivoire, Swaziland, and Mozambique 
were weighted to account for the probability-proportional-
to-size sampling. 
To estimate the effect of sex on attrition, Cox proportional 
hazards regression models were used to estimate unadjusted and 
adjusted hazard ratios, 95% confidence intervals, and p-values. 
Multivariate models included only cases with complete data 
for sex, age, CD4 count, WHO HIV disease stage, and ART 
regimen. The proportional hazards assumption was assessed 
using visual methods and the Grambsch and Therneu test (1). 
For all countries, a shared frailty model was used to account for 
intrafacility correlation. Chi-square tests were used to compare 
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distributions of categorical variables, and t-tests were used to 
compare distributions of continuous variables between men 
and women. Attrition at 6-month intervals after ART initiation 
was analyzed using the Kaplan-Meier product-limit estimate 
of the survivor function. 
The sample sizes in the six countries ranged from 1,457 to 
3,682, with a total of 13,175 records analyzed (Table 2). In 
each country, 61%–67% of ART enrollees were women. In 
each country, men were significantly older than women at 
ART initiation. Median age range for men was 37–40 years, 
and for women was 32–35 years.
Compared with women, median CD4 count at ART ini-
tiation was significantly lower among men in Côte d’Ivoire 
(119/µL compared with 155/µL), Swaziland (121/µL com-
pared with 161/µL), and Uganda (128/µL compared with 
144/µL). Median CD4 count was lower for men compared 
with women in Mozambique, Zambia, and Tanzania, although 
these differences were not statistically significant (p>0.05).
In all countries, men initiated ART at a more advanced 
WHO disease stage (Table 2). For example, a higher proportion 
of men than women initiated ART at WHO stage IV disease 
in Côte d’Ivoire (26% compared with 21%), Swaziland (18% 
compared with 10%), Mozambique (20% compared with 
13%), Zambia (11% compared with 9%), Uganda (16% com-
pared with 10%), and Tanzania (30% compared with 27%).
For both men and women across all six countries, 
nevirapine-containing first-line regimens were more common 
than efavirenz-containing or protease inhibitor–containing 
regimens, or triple nucleoside reverse transcriptase inhibitor 
regimens (Table 2). The distribution of first-line ART regi-
men choices for men differed from choices for women in all 
countries, with women more likely to be prescribed nevirapine-
containing regimens than men (Table 2). 
In all countries, point estimates for attrition during the first 
4.5 years of ART were lower for women than men (Table 3). 
This difference was statistically significant in countries in west-
ern and southern Africa, where women had 21%–27% lower 
rates of attrition in unadjusted analysis and 15%–26% lower 
rates of attrition in adjusted analysis (Table 3). In Uganda and 
Tanzania, women had 7%–18% lower rates of attrition in unad-
justed analysis and 11%–12% lower rates of attrition in adjusted 
analysis, although the associations between sex and attrition 
rates were not statistically significant in these two countries.
TABLE 1. Summary of sampling criteria and methods*† used to select adult antiretroviral therapy (ART) enrollees for retrospective cohort 
studies conducted — six African countries, 2008–2012
Characteristic Côte d’Ivoire Swaziland Mozambique Zambia Uganda Tanzania Total
Stage 1: Selection of study facilities
No. of ART clinics 124 by 
Dec 2007
31 by 
Dec 2009
152 by 
Dec 2006
322 by 
Dec 2007
286 by 
Dec 2007
210 by 
Dec 2007
No. of  enrollees at ART clinics 36,943 50,767 43,295 65,383 45,946 41,920
Clinic eligibility criteria for study Enrolled 
≥50 adults 
on ART by 
Dec 2007
All ART 
initiation 
sites 
eligible
Enrolled 
≥50 adults 
on ART by 
Dec 2006
Enrolled 
≥300 
adults on 
ART by 
Dec 2007
Enrolled 
≥300 
adults on 
ART by 
Dec 2007
Enrolled 
≥300 
adults on 
ART by 
Dec 2007
No. of study-eligible clinics 78 31 94 129 114 85 531
Estimated no. of study-eligible  
enrollees at clinics
36,110 50,767 42,234 58,845§ 41,351§ 37,728§ 267,035
No. of clinics selected 34 16 30 6 6 6 98
Stage 2: Selection of study patients
Age at ART initiation criteria for 
study enrollees
≥15 yrs ≥15 yrs ≥15 yrs ≥18 yrs ≥18 yrs ≥18 yrs
Years of ART enrollment 2004–2007 2004–2010 2004–2007 2004–2009 2004–2009 2004–2009
Planned sample size 4,000 2,500 2,600 1,500 1,500 1,500 13,600
No. of eligible study enrollees 3,682 2,510 2,596 1,457 1,472 1,458 13,175
Date of data collection Nov 2009–
March 2010
Nov 2011– 
Feb 2012
Sept–Nov 
2008
April–July 
2010
April–July 
2010
April–July 
2010
* In Côte d’Ivoire, Swaziland, and Mozambique, study facilities were randomly selected using probability-proportional-to-size sampling. In Zambia, Uganda, and 
Tanzania, study facilities were purposefully selected to represent different types of ART facilities in each country.
† In all six countries, at each selected facility, a sample frame of study-eligible ART patients was created, and simple random sampling was used to select the desired 
sample size of patient medical records.  
§ Estimate from available published data.
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TABLE 2. Enrollment characteristics of adults (N = 13,175) initiating antiretroviral therapy (ART) — six African countries, 2004–2010
Characteristic
Côte d’Ivoire*  
(N = 3,682)
Swaziland*  
(N = 2,510)
Mozambique*  
(N = 2,596)
No.
Median  
age p-value§ No.
Median  
age p-value No.
Median  
age p-value
Sex, no., and median age
Women 2,422 34 <0.001 1,621 32 <0.001 1,576 32 <0.001
Men 1,260 40 889 38 1,020 38
No.
Median  
CD4 p-value No.
Median  
CD4 p-value No.
Median  
CD4 p-value
Sex, no., and median CD4 count at 
ART initiation (cells/µL)
Women 1,811 155 <0.001 1,487 161 <0.001 1,373 161 0.063
Men 935 119 809 121 881 141
Missing data 936 — 214 — 342 —
No. (%) p-value No. (%) p-value No. (%) p-value
Sex, no., and %
Women 2,422 (67) 1,621 (65) 1,576 (62)
Men 1,260 (33) 889 (35) 1,020 (38)
WHO HIV disease stage
Stage I/II
Women 363 (19) 0.064 700 (50) <0.001 386 (39) 0.001
Men 224 (22) 260 (34) 233 (34)
Stage III
Women 987 (61) 590 (40) 451 (48)
Men 453 (53) 377 (48) 288 (46)
Stage IV
Women 331 (21) 149 (10) 136 (13)
Men 223 (26) 144 (18) 123 (20)
Missing data 1,101 (30) 290 (12) 979 (38)
Female regimens
NVP-3TC-D4T/AZT/TDF 1,219 (49) 0.077 1,153 (72) <0.001 1,430 (91) <0.001
EFV-3TC-D4T/AZT/TDF 692 (30) 372 (23) 124 (8)
Triple NRTI 90 (3) 0 — 13 (1)
PI-based 122 (4) 0 — 1 (<1)
Unknown 211 (10) 96 (5) 8 (<1)
Other 88 (5) 0 — 0 —
Male regimens
NVP-3TC-D4T/AZT/TDF 548 (42) 519 (59) 881 (85)
EFV-3TC-D4T/AZT/TDF 430 (36) 309 (35) 120 (13)
Triple NRTI 48 (3) 0 — 4 (<1)
PI-based 84 (6) 1 (<1) 2 (<1)
Unknown 110 (9) 60 (6) 13 (1)
Other 40 (3) 0 — 0 —
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Editorial Note
Equitable access to ART for both men and women is a 
principle endorsed by most African governments and inter-
national donors, including the U.S. President’s Emergency 
TABLE 2. (Continued) Enrollment characteristics of adults (N = 13,175) initiating antiretroviral therapy (ART) — six African countries, 2004–2010
Characteristic
Zambia†  
(N = 1,457)
Uganda†  
(N = 1,472)
Tanzania† 
(N = 1,458)
No.
Median  
age p-value No.
Median  
age p-value No.
Median  
age p-value
Sex, no., and median age
Women 880 34 <0.001 964 34 <0.001 973 35 <0.001
Men 575 37 502 37 484 39
No.
Median  
CD4 p-value No.
Median  
CD4 p-value No.
Median  
CD4 p-value
Sex, no., and median CD4 count at 
ART initiation (cells/µL)
Women 639 139 0.261 774 144 0.012 742 137 0.232
Men 411 127 395 128 379 121
Missing data 407 — 303 — 337 —
No. (%) p-value No. (%) p-value No. (%) p-value
Sex, no., and %
Women 882 (61) 968 (66) 974 (67)
Men 575 (39) 504 (34) 484 (33)
WHO HIV disease stage
Stage I/II
Women 326 (41) 0.029 434 (51) 0.006 225 (29) 0.006
Men 170 (34) 205 (45) 76 (20)
Stage III
Women 390 (49) 330 (39) 347 (44)
Men 277 (55) 178 (39) 192 (50)
Stage IV
Women 73 (9) 87 (10) 212 (27)
Men 54 (11) 73 (16) 113 (30)
Missing data 167 (11) 165 (11) 293 (20)
Female regimens
NVP-3TC-D4T/AZT/TDF 606 (69) <0.001 772 (80) 0.013 760 (78) 0.088
EFV-3TC-D4T/AZT/TDF 260 (29) 179 (18) 201 (21)
Triple NRTI 0 — 3 (<1) 0 —
PI-based 6 (1) 8 (1) 0 —
Unknown 0 — 0 — 0 —
Other 10 (1) 6 (1) 13 (1)
Male regimens
NVP-3TC-D4T/AZT/TDF 334 (58) 362 (72) 357 (74)
EFV-3TC-D4T/AZT/TDF 225 (39) 133 (26) 122 (25)
Triple NRTI 0 — 1 (<1) 0 —
PI-based 9 (2) 5 (1) 1 (<1)
Unknown 0 — 0 — 0 —
Other 7 (1) 3 (<1) 974 (1)
Abbreviations: WHO = World Health Organization; NVP = nevirapine; EFV = efavirenz; 3TC = lamivudine; D4T = stavudine; AZT = zidovudine; TDF = tenofovir; 
NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor. 
* Data for Côte d’Ivoire, Swaziland, and Mozambique are weighted to account for the sampling method. 
† Data were missing for two enrollees in Zambia, six in Uganda, and one in Tanzania. 
§ p-value for comparison of ART enrollee characteristics for men and women (t-test for continuous variables and chi-square test for categorical variables).
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plan for AIDS Relief and the Global Fund to Fight HIV/
AIDS, Tuberculosis, and Malaria (2,3). However, in Africa, 
proportionally more HIV-infected women are accessing ART 
services than men (4). Evaluating differences in ART enroll-
ment characteristics and treatment outcomes between men 
and women might help program managers understand these 
differences in ART enrollment and identify opportunities for 
ART program improvement.
This report has two main findings: 1) among representative 
samples of adult ART enrollees in six African countries, men 
were more likely than women to initiate ART with advanced 
HIV disease, and 2) men had higher attrition risk than women 
after ART initiation. However, differences between men and 
women in rate of attrition varied by country, being larger and 
statistically significant in western and southern African cohorts, 
but smaller and not statistically significant in cohorts from 
eastern Africa (Uganda and Tanzania).
As in other reports from African ART programs (2,5–7), 
men initiated ART at more advanced HIV disease stages than 
women. Late initiation of ART among men has commonly 
been attributed to sex differences in health-seeking behavior, 
with men considered more likely to delay access to health 
care for various reasons, including stigma, male norms that 
discourage admitting ill health, and employment responsibili-
ties (2). However, some have proposed that the prioritization 
of maternal and child health services by global and national 
public health organizations in Africa has resulted in inequitable 
access to health services, including ART (2,3). Recent reports 
suggest that whereas nearly all African countries include initia-
tives focused on women in their national AIDS strategies, only 
10% of countries are effectively engaging men and boys in the 
national AIDS response (8). To address delayed enrollment in 
ART among men, increased attention from national govern-
ments and international donors to identify and implement 
evidence-based strategies that achieve earlier HIV testing and 
ART among men might be needed (2,3). 
As in other studies from western and southern Africa (2,5,6,9), 
adjusting for possible baseline predictors of ART outcomes, 
including CD4 count, WHO HIV disease stage, age, and ART 
regimen, did not fully account for the increased rate of attrition 
among men in Côte d’Ivoire, Swaziland, Mozambique, and 
Zambia. This suggests unmeasured factors are contributing to 
either increased rates of death or loss to follow-up among men 
(2). Some reports have suggested sex differences in health-seeking 
TABLE 3. Percentage of antiretroviral therapy (ART) enrollees alive and on therapy, by years after ART initiation, and attrition* rate and risk for 
attrition, by sex — retrospective cohort studies, six African countries
Years after ART 
initiation
Côte d’Ivoire Swaziland Mozambique
Women  
%
Men 
%
Women  
%
Men 
%
Women 
%
Men 
%
0.5 81 75 86 81 84 81
1 76 70 82 77 78 73
1.5 72 66 79 74 74 69
2 67 60 76 71 71 66
2.5 63 55 74 68 69 64
3 59 51 71 64 68 59
3.5 56 48 71 63 65 53
4 51 43 68 62 65 52
4.5 47 40 65 62 62 52
Attrition rate 
Per 100 
person-years (95% CI)
Per 100 
person-years (95% CI)
Per 100 
person-years (95% CI)
Sex
Men 24.7 (22.4–27.2) 16.2 (14.4–18.2) 23.0 (19.8–26.9)
Women 18.7 (17.4–20.2) 12.4 (11.3–13.6) 17.9 (15.7–20.4)
Unadjusted risk 
for attrition HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Sex
Men Referent — Referent — Referent —
Women  0.78 (0.70–0.86) <0.001 0.78 (0.68–0.90) 0.002 0.79 (0.71–0.88) <0.001
Adjusted risk 
for attrition† HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Sex
Men Referent — Referent — Referent —
Women 0.74 (0.65–0.83) <0.001 0.85 (0.74–0.97) 0.021 0.79 (0.70–0.89) <0.001
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behavior, biologic differences in response to ART, increased 
male risk for opportunistic infections, worse adherence to ART 
pill-taking among men, or background differences in mortality 
rates by sex in the general population are responsible for higher 
attrition rates among men taking ART (2). 
In this analysis, although rates of attrition were marginally 
higher among men than women in Uganda and Tanzania, the 
effect of sex on attrition risk was smaller than that observed 
in cohorts from western and southern Africa. This might 
indicate variations in the effect of sex on attrition risk by 
country or region. One possible explanation is that internal 
and cross-border migration patterns vary by country and 
region. Historically, cross-border migration for work, which 
is more common among men than women, varies by region 
in Africa, being most common in western (10) and southern 
Africa, where South Africa is a hub for migrant labor from 
surrounding countries (10). Further research into variations 
in the effect of sex on attrition risk by country or region might 
inform interventions to reduce rates of male attrition. 
The findings in this report are subject to at least two limita-
tions. First, missing data for certain covariates of interest at 
ART initiation might have introduced some measurement 
error, and might have affected estimates of hazard ratios. 
Second, because of differences in cohort size, there was greater 
power to detect differences in outcomes between men and 
women in Swaziland, Mozambique, and Côte d’Ivoire than in 
Zambia, Uganda, and Tanzania, which limits ability to make 
conclusions about country variations in the effect of sex on 
attrition risk.
Across six countries in Africa, men initiated ART with 
more advanced disease and had statistically significant higher 
attrition in western and southern African cohorts. Reasons 
for differences between men and women in ART enrollment 
are not fully understood but might include lack of emphasis 
by donors and national governments on the importance of 
engaging men early in ART (3). Higher attrition rates among 
men are not fully explained by traditional predictors of poor 
outcomes (e.g., low CD4 count and advanced WHO HIV 
TABLE 3. (Continued) Percentage of antiretroviral therapy (ART) enrollees alive and on therapy, by years after ART initiation, and attrition rate 
and risk for attrition, by sex — retrospective cohort studies, six African countries
Years after ART 
initiation
Zambia Uganda Tanzania
Women 
%
Men 
%
Women 
%
Men 
%
Women 
%
Men 
%
0.5 81 75 94 91 76 75
1 77 69 90 88 71 67
1.5 73 65 87 84 65 62
2 70 60 85 81 62 59
2.5 66 57 82 78 58 57
3 63 54 78 76 57 55
3.5 61 51 77 74 52 52
4 57 49 75 73 49 50
4.5 55 47 73 71 48 44
Attrition rate 
Per 100 
person-years (95% CI)
Per 100 
person-years (95% CI)
Per 100 
person-years (95% CI)
Sex
Men 22.9 (20.3–25.9) 9.9 (8.2–11.9) 25.5 (22.2–29.2)
Women 16.2 (14.5–18.1) 7.9 (6.8–9.1) 24.0 (21.7–26.6)
Unadjusted risk 
for attrition HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Sex
Men Referent — Referent — Referent —
Women 0.73 (0.62–0.86) <0.001  0.82 (0.65–1.03) 0.091 0.93 (0.78–1.10) 0.406
Adjusted risk 
for attrition HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Sex
Men Referent — Referent — Referent —
Women 0.82 (0.65–1.02) 0.079 0.88 (0.66–1.18) 0.407 0.89 (0.71–1.12) 0.311
Abbreviations: CI = confidence interval; HR = hazard ratio. 
* From death, stopping ART, or loss to follow-up.
† Multivariate analysis included only complete cases: Côte d’Ivoire (2,394), Swaziland (2,090), Mozambique (1,426), Zambia (972), Uganda (1,056), and Tanzania (938). In 
addition to sex, multivariate analysis adjusted for the following characteristics at ART initiation: age, CD4 count, World Health Organization HIV disease stage, and 
treatment regimen. 
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disease stage). Identifying and implementing evidence-based 
interventions to improve male enrollment and retention in 
ART programs is important to reduce male AIDS-related 
mortality and might contribute to prevention of new HIV 
infections in female partners (3).
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What is already known on this topic?
Evaluating differences between human immunodeficiency virus 
(HIV)-infected men and women in antiretroviral therapy (ART) 
enrollment characteristics and treatment outcomes can help 
program managers understand why proportionally more 
women than men are accessing ART.
What is added by this report?
This retrospective cohort study of six African countries found 
lower median CD4 counts and more World Health Organization 
stage IV HIV disease in men at enrollment in all six countries. In 
addition, the risk of attrition during ART was significantly higher 
in men in western and southern African countries, even after 
controlling for possible baseline predictors of ART outcomes. This 
finding suggests that unidentified factors are contributing to this 
higher attrition risk in these countries. In eastern Africa, risk for 
attrition did not differ significantly between men and women. 
What are the implications for public health practice?
Further research on country-specific reasons for differences 
between HIV-infected men and women in ART enrollment and 
in attrition while on ART are needed. The results of such studies 
could potentially identify strategies to improve early diagnosis 
and treatment among men and improve program outcomes.
